Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NRCAM
REST API REST API
Homo sapiens
NRCAM is differentially expressed in 283 experiments: 174 organism parts: amygdala, lung, ... (172 more);, 183 disease states: normal, control, ... (181 more);, 73 cell types 379 cell lines 22 compound treatments and 77 other conditions.
Synonyms Bravo, KIAA0343
Orthologs ENSCING00000007077 (Ciona intestinalis)   nrcam (Danio rerio)   Nrcam (Mus musculus)   NRCAM (Bos taurus)   Nrcam (Rattus norvegicus)   NRCAM (Gallus gallus)   Nrg (Drosophila melanogaster)   nrcam (Xenopus laevis)   NRCAM (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, plasma membrane, protein localization, protein binding, synapse assembly, axon, cell-cell adhesion, axonal fasciculation, external side of plasma membrane, axon guidance, neuron projection, integral to plasma membrane, synapse, axonogenesis, regulation of axon extension, central nervous system development, ankyrin binding, neuron migration, positive regulation of neuron differentiation, neuronal action potential propagation, clustering of voltage-gated sodium channels
InterPro Term Ig_sub, Immunoglobulin, Ig-like, Ig_sub2, Ig_I-set, Fibronectin_type3
UniProt Accession Q92823, C9J8B6, C9JF43, C9JH43, B3KRX0, C9JUR7, C9JYY6, Q75ML9, F5GYD3, E9PDA4, E9PF33, F8W774, F8W775
Search EB-eye ENSG00000091129
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, E-GEOD-6236, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, ... (33 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HL-60
2
E-GEOD-5258, E-MTAB-37
MCF7
2
E-GEOD-5258, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
373 more value(s).


Cell type

studied in E-TABM-40, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (41 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-3920, E-GEOD-19240, E-GEOD-96, E-GEOD-3998
monocyte
2
E-MEXP-2019, E-GEOD-11755
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
stromal cell
1
2
E-GEOD-3998, E-MEXP-2034, E-GEOD-10797
naive B cell
1
E-TABM-702
CD8+CD28+
1
E-MEXP-2345
67 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-2280, E-GEOD-16363, ... (60 experiments)

Factor Value U/D Experiments
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
juvenile dermatomyositis
2
E-GEOD-3307, E-MTAB-62
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
colon carcinoma
2
E-MTAB-37, E-MTAB-62
glioblastoma
2
E-GEOD-6014, E-MTAB-62
papillary thyroid carcinoma
2
E-GEOD-3467, E-GEOD-3678
177 more value(s).


Compound treatment

studied in E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (14 experiments)

Factor Value U/D Experiments
none
2
3
E-GEOD-5824, E-TABM-868, E-GEOD-412, E-GEOD-2803, E-TABM-782 ... (5 experiments)
interleukin-19 (Homo sapiens)
1
E-GEOD-7216
TGF
1
1
E-GEOD-15205
rapamycin
1
E-GEOD-5824
bacterial endotoxin
1
1
E-GEOD-3284
epidermal growth factor
1
E-GEOD-6462
16 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
127.57
1
1
E-TABM-325
137.36
1
1
E-TABM-325


Age at diagnosis
studied in E-GEOD-3494

Age years
studied in E-TABM-783

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-19246, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, E-GEOD-21138, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578

Genotype
studied in E-GEOD-22056, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-2657, E-GEOD-12773, E-GEOD-20504, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (35 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1493, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.365 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM